These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

638 related articles for article (PubMed ID: 29684379)

  • 21. Catalpol counteracts the pathology in a mouse model of Duchenne muscular dystrophy by inhibiting the TGF-β1/TAK1 signaling pathway.
    Xu DQ; Zhao L; Li SJ; Huang XF; Li CJ; Sun LX; Li XH; Zhang LY; Jiang ZZ
    Acta Pharmacol Sin; 2021 Jul; 42(7):1080-1089. PubMed ID: 32939036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The slow-release adiponectin analog ALY688-SR modifies early-stage disease development in the D2.
    Bellissimo CA; Gandhi S; Castellani LN; Murugathasan M; Delfinis LJ; Thuhan A; Garibotti MC; Seo Y; Rebalka IA; Hsu HH; Sweeney G; Hawke TJ; Abdul-Sater AA; Perry CGR
    Am J Physiol Cell Physiol; 2024 Apr; 326(4):C1011-C1026. PubMed ID: 38145301
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment with L-citrulline and metformin in Duchenne muscular dystrophy: study protocol for a single-centre, randomised, placebo-controlled trial.
    Hafner P; Bonati U; Rubino D; Gocheva V; Zumbrunn T; Gueven N; Fischer D
    Trials; 2016 Aug; 17(1):389. PubMed ID: 27488051
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Celecoxib treatment improves muscle function in mdx mice and increases utrophin A expression.
    Péladeau C; Adam NJ; Jasmin BJ
    FASEB J; 2018 Sep; 32(9):5090-5103. PubMed ID: 29723037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metformin increases peroxisome proliferator-activated receptor γ Co-activator-1α and utrophin a expression in dystrophic skeletal muscle.
    Ljubicic V; Jasmin BJ
    Muscle Nerve; 2015 Jul; 52(1):139-42. PubMed ID: 25908446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enalapril treatment discloses an early role of angiotensin II in inflammation- and oxidative stress-related muscle damage in dystrophic mdx mice.
    Cozzoli A; Nico B; Sblendorio VT; Capogrosso RF; Dinardo MM; Longo V; Gagliardi S; Montagnani M; De Luca A
    Pharmacol Res; 2011 Nov; 64(5):482-92. PubMed ID: 21689754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Taurine deficiency, synthesis and transport in the mdx mouse model for Duchenne Muscular Dystrophy.
    Terrill JR; Grounds MD; Arthur PG
    Int J Biochem Cell Biol; 2015 Sep; 66():141-8. PubMed ID: 26239309
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Validation of ultrasonography for non-invasive assessment of diaphragm function in muscular dystrophy.
    Whitehead NP; Bible KL; Kim MJ; Odom GL; Adams ME; Froehner SC
    J Physiol; 2016 Dec; 594(24):7215-7227. PubMed ID: 27570057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new therapeutic effect of simvastatin revealed by functional improvement in muscular dystrophy.
    Whitehead NP; Kim MJ; Bible KL; Adams ME; Froehner SC
    Proc Natl Acad Sci U S A; 2015 Oct; 112(41):12864-9. PubMed ID: 26417069
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proof-of-concept validation of the mechanism of action of Src tyrosine kinase inhibitors in dystrophic mdx mouse muscle: in vivo and in vitro studies.
    Sanarica F; Mantuano P; Conte E; Cozzoli A; Capogrosso RF; Giustino A; Cutrignelli A; Cappellari O; Rolland JF; De Bellis M; Denora N; Camerino GM; De Luca A
    Pharmacol Res; 2019 Jul; 145():104260. PubMed ID: 31059789
    [TBL] [Abstract][Full Text] [Related]  

  • 31. AdipoRon, a new therapeutic prospect for Duchenne muscular dystrophy.
    Abou-Samra M; Selvais CM; Boursereau R; Lecompte S; Noel L; Brichard SM
    J Cachexia Sarcopenia Muscle; 2020 Apr; 11(2):518-533. PubMed ID: 31965757
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nutraceutical and pharmaceutical cocktails did not improve muscle function or reduce histological damage in D2-mdx mice.
    Spaulding HR; Quindry T; Hammer K; Quindry JC; Selsby JT
    J Appl Physiol (1985); 2019 Oct; 127(4):1058-1066. PubMed ID: 31295065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improvement of Duchenne muscular dystrophy phenotype following obestatin treatment.
    González-Sánchez J; Sánchez-Temprano A; Cid-Díaz T; Pabst-Fernández R; Mosteiro CS; Gallego R; Nogueiras R; Casabiell X; Butler-Browne GS; Mouly V; Relova JL; Pazos Y; Camiña JP
    J Cachexia Sarcopenia Muscle; 2018 Dec; 9(6):1063-1078. PubMed ID: 30216693
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiple pathological events in exercised dystrophic mdx mice are targeted by pentoxifylline: outcome of a large array of in vivo and ex vivo tests.
    Burdi R; Rolland JF; Fraysse B; Litvinova K; Cozzoli A; Giannuzzi V; Liantonio A; Camerino GM; Sblendorio V; Capogrosso RF; Palmieri B; Andreetta F; Confalonieri P; De Benedictis L; Montagnani M; De Luca A
    J Appl Physiol (1985); 2009 Apr; 106(4):1311-24. PubMed ID: 19131478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bowman-Birk inhibitor attenuates dystrophic pathology in mdx mice.
    Morris CA; Selsby JT; Morris LD; Pendrak K; Sweeney HL
    J Appl Physiol (1985); 2010 Nov; 109(5):1492-9. PubMed ID: 20847128
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chronic AMPK activation evokes the slow, oxidative myogenic program and triggers beneficial adaptations in mdx mouse skeletal muscle.
    Ljubicic V; Miura P; Burt M; Boudreault L; Khogali S; Lunde JA; Renaud JM; Jasmin BJ
    Hum Mol Genet; 2011 Sep; 20(17):3478-93. PubMed ID: 21659335
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The calcineurin signal transduction pathway is essential for successful muscle regeneration in mdx dystrophic mice.
    Stupka N; Gregorevic P; Plant DR; Lynch GS
    Acta Neuropathol; 2004 Apr; 107(4):299-310. PubMed ID: 14727129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term treatment with naproxcinod significantly improves skeletal and cardiac disease phenotype in the mdx mouse model of dystrophy.
    Uaesoontrachoon K; Quinn JL; Tatem KS; Van Der Meulen JH; Yu Q; Phadke A; Miller BK; Gordish-Dressman H; Ongini E; Miglietta D; Nagaraju K
    Hum Mol Genet; 2014 Jun; 23(12):3239-49. PubMed ID: 24463621
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new therapeutic effect of fenofibrate in Duchenne muscular dystrophy: The promotion of myostatin degradation.
    Sun Z; Xu D; Zhao L; Li X; Li S; Huang X; Li C; Sun L; Liu B; Jiang Z; Zhang L
    Br J Pharmacol; 2022 Mar; 179(6):1237-1250. PubMed ID: 34553378
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Matrix metalloproteinase-9 inhibition ameliorates pathogenesis and improves skeletal muscle regeneration in muscular dystrophy.
    Li H; Mittal A; Makonchuk DY; Bhatnagar S; Kumar A
    Hum Mol Genet; 2009 Jul; 18(14):2584-98. PubMed ID: 19401296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.